East Haven, CT, United States of America

Scott A Mitchell

This inventor holds 67 USPTO granted patents and 7 published patent applications, plus 8 CIPO patents and 22 EPO patents, primarily in Syk Inhibitors (CPC class C07D). Top assignees: Gilead Connecticut, Inc., Gilead Sciences, Inc., Cgi Pharmaceuticals, Inc.. Active years: 2004-2025.

USPTO Granted Patents = 67 (Patent Applications = 7)

% Patents Active = 79.1

CIPO Patents = 8 (Patent Applications = 1)

EPO Patents = 22 (Patent Applications = 20)

Average Co-Inventor Count = 6.4

ph-index = 19

Forward Citations = 902(Granted Patents)

Forward Citations (Not Self Cited) = 517(Dec 10, 2025)

Inventors with similar research interests:

Location History:

East Haven, CT (US) (2004 - 2019)
Foster City, CA (US) (2023)
Kenmore, WA (US) (2017 - 2024)

Company Filing History:

23 out of 30

Gilead Connecticut, Inc.

patents

17 out of 946

Gilead Sciences, Inc.

patents

13 out of 13

Cgi Pharmaceuticals, Inc.

Novartis International Pharmaceutical, Ltd.

patents

8. 1 out of 1

Cellular Genomics, Inc.

Nurix Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2004-2025

Loading Chart...

Areas of Expertise:

Syk Inhibitors

Pyridones

Azabenzimidazoles

Imidazopyrazines

Bifunctional Degraders

Eneoxindoles

Tank-Binding Kinase

Imidazopyridines

6-Aminopyrazin

Pharmaceutical Compounds

Crystalline Salts

Substituted Compounds

67 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12263163 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2025-04-01),

2. 12258346 - Substituted 6-azabenzimidazole compounds (2025-03-25),

3. 12037342 - Substituted eneoxindoles and uses thereof (2024-07-16),

4. 11925631 - Substituted 6-azabenzimidazole compounds (2024-03-12),

5. 11897878 - Substituted 6-azabenzimidazole compounds (2024-02-13),

6. 11739101 - Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof (2023-08-29),

7. 11517570 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2022-12-06),

8. 11453681 - Substituted eneoxindoles and uses thereof (2022-09-27),

9. 11203591 - Substituted 6-azabenzimidazole compounds (2021-12-21),

10. 11071730 - Substituted 6-azabenzimidazole compounds (2021-07-27),

11. 10842803 - Imidazopyridines Syk inhibitors (2020-11-24),

12. 10828299 - Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2020-11-10),

13. 10344040 - Pyridone and aza-pyridone compounds and methods of use (2019-07-09),

14. 10342794 - Substituted imidazo[1,2-a]pyrazines as Syk inhibitors (2019-07-09),

15. 10253019 - Tank-binding kinase inhibitor compounds (2019-04-09),

Title: Innovator Spotlight: Scott A Mitchell - Pioneering Inventor from East Haven, CT

Introduction: Scott A Mitchell, a prolific inventor hailing from East Haven, CT, has made a significant mark in the innovation landscape with his impressive portfolio of 64 patents. His groundbreaking work is revolutionizing the fields of pharmaceuticals and disease treatment.

Latest Patents: Mitchell's recent patents revolve around the development and application of substituted 6-azabenzimidazole compounds. These compounds, along with their pharmaceutical compositions, offer promising avenues for the treatment and prevention of diseases such as HBV, HIV, cancer, and hyper-proliferative conditions by targeting hematopoietic progenitor kinase 1 (HPK1) inhibitors.

Career Highlights: Mitchell has contributed his expertise to renowned companies like Gilead Connecticut, Inc. and Gilead Sciences, Inc., where his innovative spirit and dedication have been instrumental in driving cutting-edge research and product development in the pharmaceutical sector.

Collaborations: Throughout his career, Mitchell has collaborated closely with esteemed colleagues such as Kevin S. Currie and Peter A. Blomgren. Together, they have formed a formidable team that has pushed the boundaries of scientific exploration and achieved remarkable breakthroughs in their respective fields.

Conclusion: Scott A Mitchell's remarkable journey as an inventor underscores his unwavering commitment to advancing scientific knowledge and improving healthcare outcomes. His relentless pursuit of innovation continues to inspire peers and aspiring inventors alike, setting a high standard for excellence in the realm of patents and inventions.